Advertisement

Richtlinien für Dosismodifikationen

Chapter

Zusammenfassung

Die antineoplastischen und die toxischen Nebenwirkungen der Zytostatika können durch zahlreiche Mechanismen beeinflußt werden. Tumorbedingte und tumorunabhängige Organfunktionsstörungen interferieren mit deren Aktivierung, Metabolisierung, Inaktivierung und Ausscheidung und erhöhen das Toxizitätsrisiko. Die wichtigsten dafür verantwortlich zu machenden Faktoren sind in Tabelle 1 zu-sammengefaßt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alberts DS et al (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:107–7Google Scholar
  2. Ames MM, Powis G, Kovach JS (1983) Pharmacokinetics of anticancer agents in humans. Elsevier Amsterdam-New York-Oxford 1983Google Scholar
  3. Bennett WM et al (1983) Drug prescribing in renal failure: Dosing guidelines for adults. Americ J Kidney Dis 3:155–193Google Scholar
  4. Chabner B (1982) Pharmacologic principles of cancer treatment. WB Saunders Company, Philadelphia 1982Google Scholar
  5. Dorr RT, Fritz WL (1981) Cancer chemotherapy handbook. Elsevier New YorkGoogle Scholar
  6. Ehninger G et al (1985) The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 3:109–16PubMedCrossRefGoogle Scholar
  7. Gehman RS, Taylor SG (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404–1413Google Scholar
  8. Hoagland HC (1984) Hematologic complications of cancer chemotherapy. In: Toxicity of chemotherapy. Perry MC, Yarbro JW (eds.), Grune and Stratton, Orlando, pp 433–448Google Scholar
  9. D’Incalci M et al (1986) Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res. 46:2566–2571PubMedGoogle Scholar
  10. Perry MC (1984) Hepatotoxicity of chemotherapeutic agents. In: Toxicity of chemotherapy. Perry MC, Yarbro JW (eds.) Grune and Stratton, Orlando, pp 297–316Google Scholar
  11. Pinedo HM, Chabner BA (1978–1985) Cancer chemotherapy. Vol. 1–7, Elsevier Amsterdam, New York, OxfordGoogle Scholar
  12. Schilsky RL (1984) Renal and metabolic toxicities of cancer treatment. In: Toxicity of chemotherapy. Perry MC, Yarbro JW (eds.) Grune and Stratton, Orlando, pp 317–342Google Scholar
  13. Vlaho M, Gross R (1981) Veränderte Pharmakokinetik und Dosierung von Antirheumatika, Kortikosteroiden, Zytostatika und Immunsuppressiva bei Niereninsuffizienz. Internist 22:629–635PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • U. Fink

There are no affiliations available

Personalised recommendations